Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk Cortez et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 280 patients in Philippines (March - October 2020) Study underpowered to detect differences Cortez et al., Western Pacific Surveillance and .., doi:10.5365/wpsar.2021.12.4.852 Favors HCQ Favors control
Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines
Cortez et al., Western Pacific Surveillance and Response Journal, doi:10.5365/wpsar.2021.12.4.852
Cortez et al., Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines, Western Pacific Surveillance and Response Journal, doi:10.5365/wpsar.2021.12.4.852
Nov 2021   Source   PDF  
  All Studies   Meta
Retrospective 280 hospitalized patients in the Philippines, 25 treated with HCQ, not showing any significant differences in unadjusted results.
Although the 15% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.0% lower, RR 0.85, p = 1.00, treatment 1 of 25 (4.0%), control 12 of 255 (4.7%), NNT 142.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cortez et al., 11 Nov 2021, retrospective, Philippines, peer-reviewed, 29 authors, study period March 2020 - October 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: COVID-19: Original Research Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines Karen Joyce C. Cortez,a Bernard A. Demot,a Samantha S. Bartolo,a Dexter D. Feliciano,a Verna Moila P. Ciriaco,a Imari Irish E. Labi,a Denzelle Diane M. Viray,a Jenna Charise M. Casuga,a Karol Anne B. Camonayan-Flor,a Precious Mae A. Gomez,a Marie Ellaine N. Velasquez,a Thea Pamela T. Cajulao,a Jovy E. Nigos,a Maria Lowella F. De Leon,a Domingo P. Solimen,a Angelita G. Go,a Francis M. Pizarro,a Larry C. Haya Jr,a Ray P. Aswat,a Virginia B. Mangati,a Caesar Noel I. Palaganas,a Mylene N. Genuino,a Kimberley M. Cutiyog-Ubando,a Karen C. Tadeo,a Marienelle L. Longid,a Nowell Benedict C. Catbagan,a Joel B. Bongotan,a Beverly Anne T. Dominguez-Villara and Joeffrey B. Dalaoa Correspondence to Karen Joyce C. Cortez (email: Objective: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily targets the respiratory system. This study describes the characteristics associated with mortality among patients infected with SARS-CoV-2 at a single hospital in Baguio City, Philippines. Methods: We reviewed medical records (including history, laboratory results and treatment regimen) of 280 confirmed COVID-19 patients admitted to a single hospital during March–October 2020. Clinical characteristics and outcomes (frequency and type of complication, recovery rate and mortality) were evaluated. Multiple logistic regression was used to analyse factors associated with mortality. Results: The mean age of COVID-19 patients was 48.4 years and the female-to-male ratio was 1.8:1. Hypertension, cardiovascular disease (CVD) and diabetes were the most frequent comorbidities reported. Common presenting symptoms were respiratory and constitutional, with 41% of patients not reporting symptoms on admission. Patients with moderate, severe and critical disease comprised 45%, 8% and 4%, respectively. A total of 15% had complications, health careassociated pneumonia being the most frequent complication. The recovery rate was 95%; 5% of patients died, with multiorgan failure being the most common cause. The presence of CVD, chronic kidney disease, prolonged prothrombin time and elevated lactate dehydrogenase (LDH) were associated with mortality. Discussion: Most COVID-19 patients in our population had asymptomatic to moderate disease on admission. Mortality from COVID-19 was associated with having CVD, chronic kidney disease, elevated LDH and prolonged prothrombin time. Based on these results, we emphasize that people should take all necessary precautions to avoid infection with SARS-CoV-2. C oronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily targets the respiratory system. In December 2019, an epidemiological alert was released in China following a rise in cases of pneumonia of unknown cause. The Philippines announced its first confirmed case on 31 January 2020.1,2 The World Health Organization (WHO) officially declared a global pandemic on 11 March 2020, by which time the Philippines already had 49 confirmed cases, largely in the National Capital Region.2 Baguio City is located north of Manila, within the Cordillera Central mountain range in northern Luzon. The estimated population is 345 000, with adults (aged 19–60 years) and those aged over 60 years comprising 52% and 6.6% of the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop